New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

Discover what makes Paris's biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, ...

He led or co-led investments in Tidal Therapeutics (acquired by Sanofi for $160M upfront + $310M in milestones) and Vedere Bio (acquired by Novartis for $150M upfront + $130M in milestones), and ...

Formation Bio can fill that gap, with the capital, drug development capabilities, model, ... He led or co-led investments in Tidal Therapeutics (acquired by Sanofi for $160M upfront + $310M in ...

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of ...